Indeed, we found that pretreatment of lymphoma cells with high-dose AA significantly increased their immunogenicity as evidenced by increased percent killing of lymphoma cells by 15% and 21% of control by CD8+ T cells when combined at 5:1 and 10:1 effector:target cell ratios, respectively (t test, P < 0.05; Fig. 2A). The gene discussed is CD8A; the disease is lymphoma.